Cargando…

Body fat composition as predictive factor for treatment response in patients with newly diagnosed multiple myeloma – subgroup analysis of the prospective GMMG MM5 trial

INTRODUCTION/BACKGROUND: Obesity is a well-known risk factor for malignant tumors and increased body mass index (BMI) is correlated to the risk of developing multiple myeloma (MM). The correlation of body fat composition with disease activity, adverse events and treatment response of MM patients has...

Descripción completa

Detalles Bibliográficos
Autores principales: GroΔ, Jonathan P., Nattenmüller, Johanna, Hemmer, Stefan, Tichy, Diana, Krzykalla, Julia, Goldschmidt, Hartmut, Bertsch, Uta, Delorme, Stefan, Kauczor, Hans-Ulrich, Hillengass, Jens, Merz, Maximilian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5620270/
https://www.ncbi.nlm.nih.gov/pubmed/28978130
http://dx.doi.org/10.18632/oncotarget.19536
_version_ 1783267552134168576
author GroΔ, Jonathan P.
Nattenmüller, Johanna
Hemmer, Stefan
Tichy, Diana
Krzykalla, Julia
Goldschmidt, Hartmut
Bertsch, Uta
Delorme, Stefan
Kauczor, Hans-Ulrich
Hillengass, Jens
Merz, Maximilian
author_facet GroΔ, Jonathan P.
Nattenmüller, Johanna
Hemmer, Stefan
Tichy, Diana
Krzykalla, Julia
Goldschmidt, Hartmut
Bertsch, Uta
Delorme, Stefan
Kauczor, Hans-Ulrich
Hillengass, Jens
Merz, Maximilian
author_sort GroΔ, Jonathan P.
collection PubMed
description INTRODUCTION/BACKGROUND: Obesity is a well-known risk factor for malignant tumors and increased body mass index (BMI) is correlated to the risk of developing multiple myeloma (MM). The correlation of body fat composition with disease activity, adverse events and treatment response of MM patients has not been investigated yet. PATIENTS AND METHODS: A subgroup of 108 patients from a single institution enrolled in the prospective GMMG-MM5 trial, who received a whole-body low-dose computed tomography (WBLDCT) before induction therapy, were included in this study. Body fat composition was measured in WBLDCT for each patient, divided in the compartments abdomen, pelvis, thigh and further categorized in subcutaneous (SAT) and visceral adipose tissue (VAT). The correlation of these parameters with disease activity (M protein, plasma cell count, LDH, CRAB-criteria), adverse cytogenetics, adverse events and treatment response were evaluated. RESULTS: Significant reciprocal correlation was found between adverse cytogenetics and VAT of the abdomen and pelvis, respectively (gain 1q21: p=0.009 and p=0.021; t(4;14): p=0.038 and p=0.042). No correlation of VAT or SAT with adverse events was observed. Significant reciprocal correlation was observed between abdominal (p=0.03) and pelvic (p=0.035) VAT and treatment response. Abdominal VAT remains significant (p=0.034) independently of revised ISS stage and treatment. The BMI did not show a significant correlation with treatment response or investigated cytogenetics. CONCLUSION: Based on the clinically relevant difference in treatment outcome depending on VAT and SAT, excessive body fat of abdomen and pelvis might be a predictive factor for poor treatment response. Further influences in this context should be considered as well, e.g. chemotherapy dosing and body fat metabolism. Further studies are necessary to investigate this hypothesis.
format Online
Article
Text
id pubmed-5620270
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Impact Journals LLC
record_format MEDLINE/PubMed
spelling pubmed-56202702017-10-03 Body fat composition as predictive factor for treatment response in patients with newly diagnosed multiple myeloma – subgroup analysis of the prospective GMMG MM5 trial GroΔ, Jonathan P. Nattenmüller, Johanna Hemmer, Stefan Tichy, Diana Krzykalla, Julia Goldschmidt, Hartmut Bertsch, Uta Delorme, Stefan Kauczor, Hans-Ulrich Hillengass, Jens Merz, Maximilian Oncotarget Research Paper INTRODUCTION/BACKGROUND: Obesity is a well-known risk factor for malignant tumors and increased body mass index (BMI) is correlated to the risk of developing multiple myeloma (MM). The correlation of body fat composition with disease activity, adverse events and treatment response of MM patients has not been investigated yet. PATIENTS AND METHODS: A subgroup of 108 patients from a single institution enrolled in the prospective GMMG-MM5 trial, who received a whole-body low-dose computed tomography (WBLDCT) before induction therapy, were included in this study. Body fat composition was measured in WBLDCT for each patient, divided in the compartments abdomen, pelvis, thigh and further categorized in subcutaneous (SAT) and visceral adipose tissue (VAT). The correlation of these parameters with disease activity (M protein, plasma cell count, LDH, CRAB-criteria), adverse cytogenetics, adverse events and treatment response were evaluated. RESULTS: Significant reciprocal correlation was found between adverse cytogenetics and VAT of the abdomen and pelvis, respectively (gain 1q21: p=0.009 and p=0.021; t(4;14): p=0.038 and p=0.042). No correlation of VAT or SAT with adverse events was observed. Significant reciprocal correlation was observed between abdominal (p=0.03) and pelvic (p=0.035) VAT and treatment response. Abdominal VAT remains significant (p=0.034) independently of revised ISS stage and treatment. The BMI did not show a significant correlation with treatment response or investigated cytogenetics. CONCLUSION: Based on the clinically relevant difference in treatment outcome depending on VAT and SAT, excessive body fat of abdomen and pelvis might be a predictive factor for poor treatment response. Further influences in this context should be considered as well, e.g. chemotherapy dosing and body fat metabolism. Further studies are necessary to investigate this hypothesis. Impact Journals LLC 2017-07-25 /pmc/articles/PMC5620270/ /pubmed/28978130 http://dx.doi.org/10.18632/oncotarget.19536 Text en Copyright: © 2017 GroΔ et al. http://creativecommons.org/licenses/by/3.0/ This article is distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0/) (CC-BY), which permits unrestricted use and redistribution provided that the original author and source are credited.
spellingShingle Research Paper
GroΔ, Jonathan P.
Nattenmüller, Johanna
Hemmer, Stefan
Tichy, Diana
Krzykalla, Julia
Goldschmidt, Hartmut
Bertsch, Uta
Delorme, Stefan
Kauczor, Hans-Ulrich
Hillengass, Jens
Merz, Maximilian
Body fat composition as predictive factor for treatment response in patients with newly diagnosed multiple myeloma – subgroup analysis of the prospective GMMG MM5 trial
title Body fat composition as predictive factor for treatment response in patients with newly diagnosed multiple myeloma – subgroup analysis of the prospective GMMG MM5 trial
title_full Body fat composition as predictive factor for treatment response in patients with newly diagnosed multiple myeloma – subgroup analysis of the prospective GMMG MM5 trial
title_fullStr Body fat composition as predictive factor for treatment response in patients with newly diagnosed multiple myeloma – subgroup analysis of the prospective GMMG MM5 trial
title_full_unstemmed Body fat composition as predictive factor for treatment response in patients with newly diagnosed multiple myeloma – subgroup analysis of the prospective GMMG MM5 trial
title_short Body fat composition as predictive factor for treatment response in patients with newly diagnosed multiple myeloma – subgroup analysis of the prospective GMMG MM5 trial
title_sort body fat composition as predictive factor for treatment response in patients with newly diagnosed multiple myeloma – subgroup analysis of the prospective gmmg mm5 trial
topic Research Paper
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5620270/
https://www.ncbi.nlm.nih.gov/pubmed/28978130
http://dx.doi.org/10.18632/oncotarget.19536
work_keys_str_mv AT grodjonathanp bodyfatcompositionaspredictivefactorfortreatmentresponseinpatientswithnewlydiagnosedmultiplemyelomasubgroupanalysisoftheprospectivegmmgmm5trial
AT nattenmullerjohanna bodyfatcompositionaspredictivefactorfortreatmentresponseinpatientswithnewlydiagnosedmultiplemyelomasubgroupanalysisoftheprospectivegmmgmm5trial
AT hemmerstefan bodyfatcompositionaspredictivefactorfortreatmentresponseinpatientswithnewlydiagnosedmultiplemyelomasubgroupanalysisoftheprospectivegmmgmm5trial
AT tichydiana bodyfatcompositionaspredictivefactorfortreatmentresponseinpatientswithnewlydiagnosedmultiplemyelomasubgroupanalysisoftheprospectivegmmgmm5trial
AT krzykallajulia bodyfatcompositionaspredictivefactorfortreatmentresponseinpatientswithnewlydiagnosedmultiplemyelomasubgroupanalysisoftheprospectivegmmgmm5trial
AT goldschmidthartmut bodyfatcompositionaspredictivefactorfortreatmentresponseinpatientswithnewlydiagnosedmultiplemyelomasubgroupanalysisoftheprospectivegmmgmm5trial
AT bertschuta bodyfatcompositionaspredictivefactorfortreatmentresponseinpatientswithnewlydiagnosedmultiplemyelomasubgroupanalysisoftheprospectivegmmgmm5trial
AT delormestefan bodyfatcompositionaspredictivefactorfortreatmentresponseinpatientswithnewlydiagnosedmultiplemyelomasubgroupanalysisoftheprospectivegmmgmm5trial
AT kauczorhansulrich bodyfatcompositionaspredictivefactorfortreatmentresponseinpatientswithnewlydiagnosedmultiplemyelomasubgroupanalysisoftheprospectivegmmgmm5trial
AT hillengassjens bodyfatcompositionaspredictivefactorfortreatmentresponseinpatientswithnewlydiagnosedmultiplemyelomasubgroupanalysisoftheprospectivegmmgmm5trial
AT merzmaximilian bodyfatcompositionaspredictivefactorfortreatmentresponseinpatientswithnewlydiagnosedmultiplemyelomasubgroupanalysisoftheprospectivegmmgmm5trial